A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands — DOVE

ACC Clinical Trial

Official title:
A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE)

Status Completed

Clinical Trial Summary

This is a non-randomized, phase II, open label study of dovitinib in patients with progressive, recurrent and/or metastatic adenoid cystic carcinoma (ACC). The primary purpose of this study is to assess the anti-cancer effects of dovitinib in this population in order to evaluate whether dovitinib is worthy of further study in patients with progressive ACC.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

ACC
Carcinoma
Carcinoma, Adenoid Cystic
Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Recurrent Adenoid Cystic Carcinoma of the Salivary Glands
Salivary Gland Cancers
Salivary Gland Neoplasms

Clinical Trial Details

NCT number	NCT01678105
Study type	Interventional
Source	Ontario Clinical Oncology Group (OCOG)
Contact
Status	Completed
Phase	Phase 2
Start date	November 2012
Completion date	September 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06066333` - Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma	Phase 2
Completed	`NCT01262235` - A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients	Phase 1/Phase 2
Completed	`NCT01898715` - Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma	Phase 1